Andrew Eisenberger, MD
Hematology · New York, NYNPI 1962528794
Payments from drug & device makers
What this record shows
This record is dominated by education: $15 of the $15 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for hematology clinicians in NY, where the typical reported total is $619.
Across 1 payment — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15
Across 9 payments — averaging $24,874 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$168K
- Novo Nordisk AS$55K
What the payments were for
- Education$15100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $15 |
How this compares
$15 in reported general payments places this provider in the 10th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 38 | $527,468 |
| OjjaaraMomelotinib Dihydrochloride | 17 | $488,394 |
| Lenalidomide | 32 | $383,636 |
| JakafiRuxolitinib Phosphate | 14 | $242,266 |
| TasignaNilotinib Hcl | 12 | $215,725 |
| EliquisApixaban | 134 | $119,026 |
| OxycontinOxycodone Hcl | 32 | $109,032 |
| XareltoRivaroxaban | 65 | $61,233 |
| Fondaparinux Sodium | 23 | $34,273 |
| ProcritEpoetin Alfa | 15 | $19,096 |
| Imatinib Mesylate | 13 | $15,742 |
| Enoxaparin Sodium | 46 | $14,815 |
| LovenoxEnoxaparin Sodium | 11 | $4,951 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $4,914 |
| Hydroxyurea | 145 | $3,581 |
Paid to pharmacies, not to this prescriber.
Other hematology in New York
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.